En développement
Business·6 sa önceRésumé IA
Zealand Pharma Faces Setbacks, Shifts Focus to Promising Amylin Drug Petrelintide
Zealand Pharma's stock dropped significantly due to high dropout rates for its weight loss drug survodutide. Investors are now focusing on its amylin-based drug, petrelintide, as the next potential growth driver, despite competition and previous efficacy concerns.
C
CNBC